OverviewChartProfileKey statisticsFinancialsNewsTraderScreen

INDIVIOR PLC DL 0,50/  GB00BN4HT335  /

Lang & Schwarz
6/27/2024  5:13:37 PM Chg. -0.200 Volume Bid5:13:37 PM Ask5:13:37 PM Market Capitalization Dividend Y. P/E Ratio
15.300EUR -1.29% -
Turnover: -		 15.300Bid Size: - 15.500Ask Size: - 2.11 bill.EUR - -
GlobeNewswire 6/6 Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update
GlobeNewswire 6/5 Addex Convenes Annual General Meeting 2024
GlobeNewswire 5/31 Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024
GlobeNewswire 5/8 Addex to Present at Bio€quity Europe 2024
GlobeNewswire 4/29 Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
GlobeNewswire 4/19 Addex to Present at the Swiss Biotech Day 2024
GlobeNewswire 4/18 Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire 4/11 Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18,...
GlobeNewswire 4/3 Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Mod...
GlobeNewswire 3/14 Addex to Present at the Bio-Europe Spring 2024 Conference
GlobeNewswire 3/5 Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire 1/31 Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.
GlobeNewswire 1/18 Adial Announces Appointment of Tony Goodman as Chief Operating Officer
GlobeNewswire 1/9 Addex to Present at the Swiss Equities Baader Conference
GlobeNewswire 1/5 Addex to Present at Biotech Showcase™ 2024
GlobeNewswire 12/14/2023 Addex Creates Treasury Shares
GlobeNewswire 11/29/2023 Addex Reports Q3 2023 Financial Results and Provides Corporate Update
GlobeNewswire 11/28/2023 Addex Convenes Extraordinary General Meeting
GlobeNewswire 11/23/2023 Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on Novem...
GlobeNewswire 11/14/2023 Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients
GlobeNewswire 11/8/2023 Addex Regains Nasdaq Listing Compliance
GlobeNewswire 11/2/2023 Addex Announces Participation in the Bio-Europe 2023 Conference
Newsfile Corp 10/31/2023 Pharma and Biotech Business Development Leaders to Discuss Psychedelics Partnering at Wonderland
GlobeNewswire 10/20/2023 Addex Completes ADS Ratio Change
GlobeNewswire 10/6/2023 Addex Announces Plan to Implement ADS Ratio Change